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Summary. We investigated the effect of prothrombotic
coagulation defects in combination with smoking and other
conventional risk factors on the risk of myocardial infarc-
tion in young women. In 217 women with a first myocar-
dial infarction before the age of 50 years and 763 healthy
control women from a population-based case—control study,
factor V Leiden and prothrombin 20210A Status were
determined. Data on major cardiovascular risk factors and
oral contraceptive use were combined with the presence or
absence of these prothrombotic mutations, and compared
between patients and controls. The overall odds ratio for
myocardial infarction in the presence of a coagulation defect
was 1-1 [95% confldence interval (CI) 0-6-1-9]. The com-
bination of a prothrombotic mutation and current Smoking
increased the risk of myocardial infarction 12-fold (95% CI
5-7-27) compared with non-smokers without a coagulation
defect. Among women who smoked cigarettes, factor V
Leiden presence versus absence increased the risk of myo-
cardial infarction by 2-0 (95% CI 0-9-4-6), and prothrombin
20210A presence versus absence had an odds ratio of 1-0
(95% CI 0-3-3-5). We conclude that factor V Leiden and
prothrombin 2021OA do not add substantially to the overall
risk of myocardial infarction in young women. However, in
women who smoke, the presence of factor V Leiden in-
creased the risk of myocardial infarction twofold.
Keywords: myocardial infarction, factor V Leiden, pro-
thrombin 20210A mutation, risk factors, oral contra-
ceptives.
Factor V Leiden and the prothrombin 20210A variant are
prothrombotic mutations that predispose for venous throm-
bosis (Bertina et cd, 1994; Poort et cd, 1996; Bloemenkamp
et al, 1995); however, their contribution to the risk of
arterial thrombosis is less clear. Positive associations were
found in speciflc groups of patients, especially young
patients with other cardiovascular risk factors or patients
with normal coronary angiographies (Rosendaal et al,
1997a, b; Inbal et al, 1999; Mansourati et al, 2000; Van
de Water et al, 2000; Burzotta et al, 2002), but these could
not be conflrmed in several other studies (Emmerich et al,
1995; Prohaska et al, 1995; Ridker et al, 1995a, 1999; Van
Bockxmeer et al, 1995; Ardissino et al, 1996; Corral et al,
1997; Amowitz et al, 1999; Croft et al, 1999; Irani-Hakime
et al, 2001; Smiles ei al, 2002). In a study of 84 women
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with myocardial infarction aged below 44 years of age,
factor V Leiden increased the risk of myocardial infarction
2-4-fold, an effect which seemed to be confined to current
smokers (Rosendaal et al, 1997b). A similar effect of other
major cardiovascular risk factors was seen for carriers of
prothrombin 20210A (Rosendaal et al, 1997a).
Factor V Leiden enhances the effect of oral contracep-
tives, with a synergistic risk of venous thrombosis 35-fold
greater than that of non-users without factor V Leiden
(Vandenbroucke et al, 1994). Moreover, the increased risk
of thrombosis is most pronounced in the first year of oral
contraceptive use, especially in women with thrombophilic
defects (Herings et al, 1999; Bloemenkamp et al, 2000;
Vandenbroucke et al, 2000). For the prothrombin 20210A
mutation and oral contraceptive use, a synergistic risk has
been found for deep vein thrombosis and cerebral venous
Sinus thrombosis (Martinelli et al, 1998; 1999).
Oral contraceptives increase the risk of myocardial
infarction with estimated relative risks between 2 and 5,
which may be reduced by abstinence from smoking and a
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blood pressure check prior to prescription of oral contra-
ceptives (WHO Collaborative Study of Cardiovascular Dis-
ease and Steroid Hormone Contraception, 1997). We
recently found that modern Iow-dose oral contraceptives
still increase the risk of myocardial infarction twofold and
that the risk associated with oral contraceptive use was
similar in women with and without a prothrombotic
mutation (Tanis et al, 2001).
In this nationwide population-based case-control study
we examined the effect of factor V Leiden and prothrombin
2021OA on the flrst myocardial infarction in women aged
less than 50 years. Furthermore, we aimed to assess
whether these mutations would help to identify women at
a high risk when smoking cigarettes, with a history of
hypertension, diabetes or hypercholesterolaemia, and dur-
ing oral contraceptive use.
MATERIALS AND METHODS
Design. The Risk of Arterial Thrombosis In relation with
Oral contraceptives (RATIO) study is a population-based
case-control study on the association between oral contra-
ceptive use and acute myocardial infarction, performed in
the Netherlands (Tanis et cd, 2001). We included patients
from all eight university hospitals äs well äs eight sur-
rounding hospitals and a population-based control group
matched for age, Index year and area of residence. In the
first phase of the study a standardized mailed questionnaire
was completed by 248 patients and 925 controls, and in the
second phase either blood samples were drawn or buccal
swabs collected for the determination of factor V Leiden and
prothrombin 2021 OA Status. The Ethics Committees of all
participating hospitals approved the study protocol.
Patients and control women. Patients were women aged
between 18 and 49 years with a flrst myocardial infarction
who were all hospitalized in university or general hospitals
in the Netherlands in the period between January 1990 and
October 1995 (see Appendix for participating centres).
Medical records and discharge letters were reviewed for
conflrmation of the diagnostic criteria for myocardial
infarction, which was deflned by the presence of Symptoms,
diagnostic elevated cardiac enzymes, and electrocardio-
graphic changes indicative of myocardial infarction (Fried
et al, 1991). We obtained DNA from 204 patients by venous
blood draw and from 13 patients by mailed-in buccal swabs.
Control subjects were women aged between 18 and
49 years without a prior history of myocardial infarction,
stroke or severe peripheral arterial disease, and recruited
from the same areas using random digit dialling (Hartge
et al, 1984). In the control group, DNA was obtained from
763 women (638 women participated in venous blood draw
and from 131 women we obtained a buccal swab). Overall
response was 75%.
Demographic characteristics. Data regarding cigarette smo-
king, a history of hypertension, diabetes and hypercholes-
terolaemia, height and weight, educational level, a family
history of cardiovascular disease and oral contraceptive use
were collected with standardized mail questionnaires in
1997 and 1998. All questions elicited information from a
time period preceding the index date, i.e. the date of
myocardial infarction in patients and the mid-year of the
same year in controls. Current smokers were those who
reported smoking regularly in the year before the index
date. Women were classified äs having a history of
hypertension, diabetes or hypercholesterolaemia when they
reported a physician's diagnosis or were taking medication
for these conditions before the index date. At the time of
venous blood draw, we were able to conflrm the data on
three metabolic risk factors: hypertension, diabetes and
hypercholesterolaemia. A women was classified äs hyper-
tensive when using antihypertensive medication, having a
systolic blood pressure of 160 mmHg or higher, or a
diastolic blood pressure of 9 5 mmHg or higher at the time
of venepuncture. Blood pressure was measured in a supine
Position after 5 min rest. Diabetes was deflned äs the use of
glucose lowering medication or a non-fasting glucose above
11Ό mmol/1. Hypercholesterolaemia was deflned äs the use
of medication for this condition or a non-fasting serum total
cholesterol above 6-5 mmol/1. Body mass index was calcu-
lated äs body weight (kg) divided by height squared (m2).
Women who had a body mass index >27·3 kg/m2 were
classified äs obese to facilitate comparisons with earlier
reports (Fried et al, 1991; Rosendaal et al, 1997a). A family
history of cardiovascular disease was defined äs the presence
of myocardial infarction, stroke or peripheral vascular
disease under 60 years of age in a first-degree relative.
Women were classified äs current oral contraceptive users if
they had used oral contraceptives in the month before the
index date.
Blood collection and laboratory analysis. Venepunctures-
and buccal swab collections were performed between June
1998 and May 2000. Blood samples were drawn from the
antecubital vein into two Sarstedt Monovette® tubes con-
taining ΟΊ06 mol/1 trisodium citrate and centrifuged for
20 min at 4500 r.p.m. High-molecular-weight DNA was
isolated from the white blood cells by a salting-out process
(Miller et al, 1988) or from buccal swabs (Thomson et al,
1992). Cotton swabs in sodium dodecyl sulphate (SDS)-
proteinease K solution were incubated for 2 h at 65°C after
arrival and centrifuged for l min at 1000 r.p.m. Potassium
acetate was added to a final concentration of 1-6 mol/1 and
after 15 min incubation on ice, protein were removed using
chloroform/isoamylalcohol (24 : 1) treatment. The DNA
was stored at 4°C until amplification. Genetic analysis of the
factor V Leiden mutation (1691 G —> A) was performed
with the polymerase chain reaction äs we described previ-
ously (Bertina et al, 1994). The prothrombin variant
(20210 G —» A) was determined by the presence of the
Hindlll restriction site in the polymerase chain reaction
fragment also described previously (Poort et al, 1996). The
technician who performed DNA analyses was blinded to
whether a blood sample was from a patient or a control.
Statistical analysis. The prevalence of factor V Leiden and
prothrombin 20210A was calculated in patients and
controls separately. Univariate odds ratlos with 95% con-
fidence intervals (95% CI) were calculated for the relation-
ship between coagulation defects or other cardiovascular
risk factors and myocardial infarction äs a measure of
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relative nsk The effect of a combmation of nsk factors i e
coagulation defects and oral contraceptive use or coagula-
tion defects and major cardiovascular nsk factors were
analysed by calculatmg odds ratlos in subjects with either
one or both of these nsk factors, compared with those with
neither nsk factor Adjustment when appropnate, was
performed by multivariate regression models that controlled
for age, mdex year and area of residence
RESULTS
Risk factor variables
The mean age of the 217 patients with a flrst myocardial
mfarction was 42 8 years, and that of 763 control women
387 years (Table I) As expected, patients more frequently
had a history of hypertension (25% vs 6%) diabetes (5% vs
1%) or hypercholesterolaemia (11% vs 3%) Vahdation of
the metabolic nsk factors at the time of blood samplmg
confirmed the diagnoses of hypertension (82% vs 12%),
diabetes (11% vs 2%) or hypercholesterolaemia (62% vs
16%) However, äs the result of blood pressure-lowenng
drugs äs well äs lipid-lowermg drugs, prescribed m patients
after myocardial mfarction, the percentages for hyperten-
sion and hyperlipidaemia far exceeded those documented
pnor to myocardial mfarction (physician's diagnosis or drug
therapy) The most stnking difference between patients and
controls was the percentage smokmg at the mdex date 83%
m patients versus 42% m controls
Prothrombotic mutations
The factor V Leiden mutation was found in 13/217 patients
(6 0%), and m 42/763 healthy control women (5 5%) The
prothombin 20210A mutation was present m 5/217 (2 3%)
patients and 18/763 control women (2 3%) This yielded an
overall odds ratio of l l (95% CI 06-21) for flrst
myocardial mfarction in the presence of factor V Leiden
and l 0 (95% CI 04-2 7) for the prothrombm mutation
(Table II) There were no homozygous carners of either
factor V Leiden or prothrombm 20210A two control
women were heterozygous for both mutations Eighteen
patients (8 3%) and 58 controls (7 6%) were carners of
either factor V Leiden or prothrombm 20210A Adjustment
for the stratification variables (age mdex year and area of
residence) did not affect the estimates In women with a
prothrombotic mutation aged less than 35 years, the relative
risk of myocardial mfarction was l 6 (95% CI 0 4-5 8) and
in women older than 35 yedrs it was 0 9 (95% CI 0 5-1 7)
The difference m these odds ratios was completely determmed
by factor V Leiden (and not by prothrombm 20210A) with a
relative nsk of 2 3 (95% CI 0 6-8 6) for women less than
35 years and 0 9 (95% CI 0 4-1 9) for women older than
35 years
Combmed effect of prothrombotic mutations
and cardiovascular nsk factors
The nsk of myocardial mfarction was increased more than
12-fold among smokmg women with a coagulation defect
compared with non-smokers without a coagulation defect
indicating a synergistic effect of both nsk factors The
Coagulation Oefects and Myocardial Infarctwn 473
Table I Baselme charactenstics of women with flrst myocardial
mfarction and control women
Patients Control women
(n = 217) N (%) (n = 763) N (%)
Age (year)
Mean (SD) 428(61) 387 (80 )
Range 24-49 18-49
Caucasian ethmcity* 206 (95) 719 (95)




Secondary school 80(37) 332(44)
Higher education 24(11) 198(26)
or umversity
History of
Hypertension 55 (25) 47 (6)
Hypercholesterolaemia* 23(11) 2 2 ( 3 )
Diabetes 11 (5) 10 (1)
Currently treated for
Hypertensionf 177 (82) 92 (12)
Hypercholesterolaemiat 134 (62) 125 (16)
Diabetesf 23 (11) 12 (2)
Body kass Index (mean SD)* 255 (50) 2 3 4 ( 3 7)
Cigarette smokmg
Never 19 (9) 248 (32)
Former 18 (8) 198 (26)
Current 181 (83) 319 (42)
Family history of 141(67) 262(37)
cardiovascular disease*
Data are numbers (%) unless otherwise indicated N number of
patients SD Standard deviation
* Data was missing on the ethmcity of four control women oral
contraceptive use of eight control women and three patients edu-
cation level of four control women hypercholesterolaemia of five
control women cigarette smokmg of four control women family
history of cardiovasculai disease of six patients and 48 control
women
t Takmg prescnption drugs for these conditions or vahdated by a
cholesterol level > 6 5 mmol/1 non fastmg serum glucose > 11 l
mmol/I systohc blood pressure >160mmHg or diastohc blood
pressure > 95 mmHg
adjusted odds ratio for the combination of hypertension and
a coagulation defect was 11 l (95% CI l 1-114) although
this was based on very small numbers The results presented
m Table III mdicate that the combmed effect of a coagulation
defect and either hypercholesterolaemia or obesity did not
exceed the separate effect of the two factors For diabetes
either the small sample size or an absence of carners of a
coagulation defect did not allow analyses for interaction
When we combmed the presence of one or more of the
metabolic risk factors (hypertension, hypercholesterolae-
mia diabetes and obesity) the odds ratio did not differ
between women without (OR 3 3 95% CI 2 4-4 6) or with
(OR 33 95% CI l 4-7 7) a coagulation defect The risk
of myocardial mfarction was increased twofold for oral
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Table H. Prevalence of factor V Leiden and 20210A mutation m
the prothrombm gene m 217 women with flrst myocardial mfarc-






















1 1 (0 6-2 1)
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1 1 (0 6-1 9)
N, number of patients
*GG mdicates wdd-type genotype AG mdicates heterozygosity for
the mutation
tReference category
{Two control women were heterozygous for both factor V Leiden
and prothrombm 20210A
contraceptive users without a prothrombotic mutation (OR
2 l, 95% CI l 5-3 0) and was not more mcreased m those
with a prothrombotic mutation (OR l 9, 95% CI 0 6-5 5)
Smokers
Table IV shows that, m the subgroup of smokers, the
presence of factor V Leiden mcreased the nsk of myocar-
dial mfarction by 2 0 (95% CI 0 9-4 6), with an adjusted
odds ratio of 3 4 (95% CI 13-92) In carners of
prothrombm 20210A who smoked, no additional mcrease
in nsk was found, with an odds ratio of l 0 (95% CI 0 3-
35) (adjusted OR 11, 95% CI 03-47) The combmed
effect of smokmg, oral contraceptive use and a coagula-
tion defect had a high, adjusted odds ratio of 34 (95% CI
5 5-179) compared with women without any of these
nsk factors
Combmation of cardiovascular nsk factors
The contribution of conventional risk factors (smokmg,
hypertension, diabetes, hypercholesterolaerma and obesity)
was far more than that of factor V Leiden, and in only
four patients (2%) none of these risk factors were found,
compared with 128 controls (18%) The nsk of myocar-
dial mfarction mcreased very sharply with the number of
risk factors observed those with one risk factor had a
Table III. Effect of smokmg, hypertension, hypercholesterolaemia diabetes obesity and oral contraceptive use with and without a coagulation
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Odds ratio (95% CI)
10*
0 5 (0 1-2 3)
6 5 (4 3-9 7)
125 (57-27)
10*
1 2 (0 7-2 2)
4 2 (2 7-6 6)
11 1 (1 1-114)
1*




1 2 (0 6-2 0)
40 (16-98)
1*
0 9 (0 4-1 9)
2 6 (1 7-3 8)
3 7 (13-102)
1*
1 4 (0 7-2 7)
2 1 (1 5-3 0)
1 9 (0 6-5 5)
N number of patients FVL factor V Leiden Odds ratlos adjusted for the stratification variables (age area of residence and calendar year)
*Reference category
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2 0 (0 9-4 6)
1t
1 0 (0 3-3 5)
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N, number of patients
*0dds ratios adjusted for the stratification variables (age area of residence and calendar year)
tReference category
GG mdicates wüd-type genotype AG mdicates heterozygosity for the Imitation AA (homozygosity for the mutation) was not found
2 8-fold mcreased nsk, those with two nsk factors had a
14-fold mcreased nsk, those with three nsk factors a 26-
fold mcreased nsk, those with four nsk factors a 89-fold
mcreased risk and those with flve nsk factors had an odds
ratio exceeding 140, all relative to those with no risk
factor at all
DISCUSSION
In this large population-based case-control study the preval-
ence of factor V Leiden and prothrombm 20210A did not
differ between patients and control women Factor V Leiden
did not exert an effect on the overall nsk of myocardial
mfarction (OR l l, 95% CI 0 6-2 1), nor did prothrombm
20210A (OR l 0, 95% CI 0 4-2 7) The risk of myocardial
mfarction was further mcreased between twofold and three-
fold by factor V Leiden among smokers, but not by
prothrombm 20210A Among very young women, deflned
äs aged below 35 years, factor V Leiden mcreased the risk of
myocardial mfarction twofold Users of low-dose oral contra-
ceptives had a twofold higher nsk than non-users (95% CI
l 5-2 8), which was not affected by the presence of a
prothrombotic mutation (Tanis et al, 2001) The combma-
tion of a coagulation defect, smokmg of cigarettes and oral
contraceptive use mcreased the risk of myocardial mfarction
34-fold
Combmed effect of prothrombotic mutatwns
and cardwvasLular mfc jactors
The mfluence of coagulation defects on myocardial mfarction
has been mvestigated since 1995 with varying outcomes
(Emmerich et al, 1995, Kontula et al, 1995, Ridker et al,
1995a, b, 1999, Van Bockxmeer et al 1995, Ardissmo et al,
1996, Arruda et al, 1997 Ferraresi et al, 1997, Rosendaal
et al, 1997a, b, Doggen et al, 1998 Eikelboom et al, 1998,
Francoei al, 1998 Croftei al, 1999 Gardemannet al, 1999,
Inbal et al, 1999, Coulet et al, 2000) Different results on the
contnbution of the coagulation defects seem to depend on
the type of population which was studied, with positive
associations m specific subgroups of young women (Holm
ei al, 1994, Rosendaal et al, 1997a, b), smokers and patients
with metabohc risk factors (Doggen et al, 1998, Inbal et al,
1999) or patients with normal coronary angiographies
(Mansourati et al, 2000)
Previously, we reported that factor V Leiden was a
determmant of myocardial mfarction m young American
women, mcreasmg the risk 2 5-fold and fourfold when other
major risk factors for myocardial mfarction were taken mto
account (Rosendaal et al, 199 7b) For the 20210A mutation,
an age-adjusted odds ratio of 4 0 (95% CI l 1-15 1) for
myocardial mfarction was found (Rosendaal et al, 1997a)
Both in the two studies by Rosendaal and colleagues and the
present study, the prevalence of smoking m young women
with myocardial mfarction was very high, 74% and 83%
respectively In the present study, we conflrmed the hypo-
thesis that smoking is a prerequisite for the effect of factor V
Leiden m arterial thrombosis, but found no effect for pro-
thrombm 20210A Possible explanations for the different
conclusions concerning metabohc risk factors in the two
studies are admixture of different cardiovascular risk factors,
i e obesity, m a heterogeneous American population or var-
lations in geographical distnbution of the prothrombotic
mutations between young women from the USA and the
Netherlands (Ridker et al, 1997, Rosendaal et al, 1998)
Strengths and limitations of the study
The present study is one of the largest case-control studies
among young women that has exammed the association
between genetic coagulation defects and the nsk of myocar-
dial mfarction Both for patients and control women the
response was high, at 80% and 73% respectively The high
percentage of oral contraceptive use m our study, almost 40%
m both patient and control gioup, also allowed us to study the
combmed effect of oral contraceptive use and two prothrom-
botic mutations on myocardial mfarction In contrast with
the risk of venous thrombosis we found no mteraction
between oral contraceptive use and these prothrombotic
mutations with regard to the nsk of myocardial mfarction
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The RATIO study is hmited by the fact that we only
studied women who survived myocardial mfarction It is
unhkely that coagulation defects play an important role m
survival of acute myocardial mfarction which is high m this
age group (Dünn et al 2000) However the possibihty thdt
the prothrombotic mutations were associated with more
severe myocardial mfarction and acute death cannot be
excluded In this case we would have underestimated the
effect of prothrombotic mutations on the nsk of myocardial
mfarction
Chmcal imphcations
Myocardial mfarction is d multicausal disease and several nsk
factors are needed before acute myocardial mfarction occurs
m young patients (Sidney et al 1996 Siscovick et al 1997)
From a climcal perspective the results of our study may have
important imphcations In the absence of an mcreased overall
nsk of myocardial mfarction m carners of the factor V Leiden
mutation or prothrombm 20210A the beneflt of screenmg
young mdividuals for these coagulation defects seems absent
In contrast our study underlmes the importance of screenmg
for high blood pressure diabetes and hypercholesterolaemia
before prescnbmg the pill Firstly because of interaction
between these conventional risk factors and oral contracept-
ive use äs descnbed m the first phase of the RATIO study
(Tams et al 2001) andsecondly the absolute risk associated
with oral contraceptive use mcreases exponentially because
of the steeply nsmg incidence of myocardial mfarction with
age (Farley et al 1998) Smoking was by far the most strikmg
nsk factor for myocardial mfarction m young women present
m over 80% of the patients compared with 42% of control
women Therefore the most important message for young
women startmg to use oral contraceptives is to have their
blood pressure measured and to stop smokmg Given the high
percentage of smokers among young women this is the most
important issue for the prevention of premature athero-
thrombotic events
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